The Scottish Medicines Consortium (SMC) has announced that the anti-fibrotic medicine nintedanib has been accepted for use by NHS Scotland for the treatment of patients with the lung scarring disease Pulmonary Fibrosis.  Action for Pulmonary Fibrosis (APF) has spearheaded a campaign for patients in Scotland with the support of patients, families and medical experts, to give patients access to life-extending anti-fibrotic drugs at the point of diagnosis.  Evidence shows that antifibrotics not only slow progression but also extend lives by up to two years or more. Until now, patients with pulmonary fibrosis in Scotland had no licensed treatment options available

Scotland: Hope for patients with pulmonary fibrosis as seen on The Hippocratic Post.